Table 6.

Measures of the effect, OR (95% CI) *, of ADs as a whole and of immunomodulatory treatments prior to hospital admission with their propensity scores on the outcome variables ^α.

		Antimalarials	Corticosteroids	cs/tsDMARDs	bDMARDs
Mortality	2.11 (0.56–7.58)	1.02 (0.29–3.58)	0.80 (0.26–2.49)	1.31 (0.60–2.90)	0.14 (0.03–0.78) *
Composite outcome	1.58 (0.44–5.63)	1.18 (0.38–3.68)	0.80 (0.28–2.33)	1.35 (0.65–2.80)	0.22 (0.04–1.14)
Complications	0.94 (0.25–3.44)	1.76 (0.56–5.55)	1.57 (0.47–5.30)	0.98 (0.47–2.02)	0.71 (0.09–5.91)

^α Propensity scores were obtained with the inverse weighting method. Outcome variables were mortality, composite outcome (mortality, mechanical ventilation, and ICU admission), and complications during the hospitalization. Predictor variables included in the logistic regression model to estimate the propensity score: age, sex, race, form of acquisition (common/nosocomial/residency), alcohol use disorder, smoking, Barthel Index score, comorbidity, Charlson Comorbidity Index, immunosuppressive/immunomodulatory treatments prior to admission (anti-malarial, glucocorticoids, cs/tsDMARDs, bDMARDs) and during hospitalization (antimalarials, tocilizumab, immunoglobulins, anakinra, baricitinib, corticosteroids), and the presence of a complication during hospitalization (38 exposure variables to calculate the propensity scores). A total of 11,174 patients hospitalized by COVID-19 were included. AD: autoimmune disease; bDMARDs: disease modifying anti-rheumatic drugs, original, biologic, or similar; cs/tsDMARDs: disease-modifying anti-rheumatic drugs, synthetic, conventional, or targeted; ICU: intensive care unit.